Bayer Schering Pharma AG and Bayer (Pty) Ltd v Pharma Dynamics and The Registrar of Patents
Yasmin* is the trade name for drospirenone and ethinyl estradiol, used mainly as an oral contraceptive.
It is also indicated in the treatment of acne. According to reports in Bloomberg, Yasmin was the number four oral contraceptive in the US during 2011. Bayer AG’s contraceptives generated $1.58 billion in sales in 2010—a sizable market by any measure.
Internationally, and particularly in the US, Yasmin has been the subject matter of class action litigation. It has also been the subject of patent litigation in South Africa. An action for the infringement of South African patent 2004/4083 was instituted against Pharma Dynamics in response to approval by the Medicines Control Council to market a competing generic product, Ruby, in South Africa.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
Yasmin, oral contraceptive, patent, South Africa
